Targeting the endocannabinoid system, and in particular cannabinoid receptor 2 (CB2), has been repeatedly proposed as a promising option against a vast array of cancer types, ranging from hematological to solid tumors [25,26,27,28,29]. Here, CNR2 is linked to cancer.